Chemotherapy and Drug Information

Safest timing of pegfilgrastim administration seems to be 72 hours after chemo

Safest timing of pegfilgrastim administration seems to be 72 hours after chemo

Safest timing of pegfilgrastim administration based on white blood cell (WBC) count seems to be 72 hours following chemotherapy.

Underinvestment in long-term cancer drug research seen as a strong influence on drug development

Drugs to treat late-stage cancers are less costly to develop than drugs for earlier-stage cancers, which may steer pharmaceutical firms toward more late-stage drug development.

Port functionality with irinotecan administration

Port functionality with irinotecan administration

Subcutaneous power ports seem to rarely function properly when administering irinotecan but function properly when the regimen changes. Is there an explanation for why this happens?

Profile of neratinib and its potential in the treatment of breast cancer

Profile of neratinib and its potential in the treatment of breast cancer

[Breast Cancer: Targets and Therapy] This research reviews the preclinical as well as clinical data on neratinib.

Standard IV administration of KCL

Standard IV administration of KCL

Is there a standard process for administering KCL through an IV?

Practices should be evaluated for cytotoxic chemotherapy extravasation

Practices should be evaluated for cytotoxic chemotherapy extravasation

This literature review sought to analyze the quality of evidence that supports management practices of cytotoxic drug extravasation.

Expensive new leukemia medication to be covered by Medicare

Expensive new leukemia medication to be covered by Medicare

Amgen's Blincyto costs about 178,000 for a standard course of treatment.

Chemotherapy less likely to benefit older patients with breast cancer

Chemotherapy less likely to benefit older patients with breast cancer

Chemotherapy does not improve survival for older women with breast cancer.

Activated neutrophils may trigger potentially fatal hemorrhage associated with some cancer treatments

Blocking the passage of immune cells could prevent dangerous complications in patients undergoing transplants or chemotherapy.

Precision medicine promising for most common type of lymphoma

Patients with a particular molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib than patients with another molecular subtype of the disease.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin) - cervical cancer

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs